Orlando, Florida, October 21st, 2015 – At the 10th International Society for the Study of Xenobiotics (ISSX) meeting, Bruker today announced the novel Molecular Drug Imager™ solution for pre-clinical drug and metabolite imaging.
MALDI-based tissue imaging for pharmaceutical development has provided researchers with a powerful technique for localizing small molecule drugs and their metabolites, or lipids, within tissue structures, providing key insights into physiological function that were unavailable with previous technologies. With its powerful software and workflow flexibility, the new Molecular Drug Imager solution is poised to take small molecule mass spectrometry imaging (MSI) to the next level by empowering fast, accurate, and thorough evaluation of drug candidates and their metabolites in model tissues and beyond.
For more than a decade, Bruker has provided industry-leading advances in hardware and methods for MALDI-based mass spectrometry imaging. The recently introduced rapifleX™ MALDI-TOF system has set new standards for speed and pixel fidelity for protein imaging and molecular histology research, while the solariX XR™ FTMS system successfully merged MALDI small molecule imaging with Isotopic Fine Structure (IFS) analysis for undisputable molecular formula specificity.
The Molecular Drug Imager leverages the unparalleled power of solariX-based small molecule imaging to provide a comprehensive analysis-to-answer imaging workflow solution to enable pharmaceutical investigators at all levels, from biomarker discovery and validation to drug development studies. Many of the top-25 pharma companies are already using earlier versions of this MSI technology in their pre-clinical efforts to complement or replace expensive workflows, such as Quantitative Whole-Body Autoradiography (QWBA), and to migrate certain animal based pre-clinical models to tissue proxies.
About the Molecular Drug Imager
Providing traditional MALDI imaging analysis functions such as combining optical and molecular images, the Molecular Drug Imager in its first workflow facilitates localizing multi-generational metabolic products of drug candidates by in silico metabolism followed by automated image generation of predicted metabolites in analyzed tissues. This results in a significant time savings through automation of this critical workflow, which is becoming commonplace in advanced laboratories worldwide.
The second advanced workflow provides a rapid discovery tool based on comprehensive statistical treatment of imaging datasets. Powered by the SCiLS lab software suite, powerful next-generation statistical algorithms such as PLSA and univariate and multivariate modalities can rapidly analyze imaging regions to identify unknown metabolites and biomarkers through spatial co-localization.
The Molecular Drug Imager solution is also being featured simultaneously at the Society for Toxicological Pathology Meeting in Minneapolis, Minnesota on October 17-21.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, Nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
Vice President, Investor Relations
Bruker Corporation T: +1 (978) 667-9580, ext. 1479
Mike Easterling Vice President, Business Unit FTMS
Bruker Daltonics Division
Tel: +1 (978) 873-0949